Optimal use of aromatase inhibitors: To lead or to follow?

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2639-2641

  Lin, Nancy U ^a   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EDITORIAL; GENETIC POLYMORPHISM; HORMONAL THERAPY; HUMAN; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT DURATION; AGED; ALLELE; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MIDDLE AGED; NOTE; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; ALLELES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECURRENCE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 34447568511     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.9447     Document Type: Editorial

References (21)

1. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
2. Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
3. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
4. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005
5. Boccardo F, Rubagotti A, Puntoni M, et al: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147, 2005
6. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
7. Kaufmann M, Jonat W, Hilfrich J, et al: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The Arno 95 Study. J Clin Oncol 25:2664-2670, 2007
8. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
9. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
10. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271, 2005
11. Coombes RC, Paridaens R, Jassem J, et al: First mature survival analysis of the Intergroup Exemestane Study: A randomized trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen. J Clin Oncol 24:9s, 2006 (LBA 527)
12. Jonat W, Gnant M, Boccardo F, et al: Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol 7:991-996, 2006
13. Punglia RS, Kuntz KM, Winer EP, et al: Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: A decision analysis. J Clin Oncol 23:5178-5187, 2005
14. Cuzick J, Sasieni P, Howell A: Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 94:460-464, 2006
15. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
16. Viale G, Regan M, Dell'Orto P, et al: Central review of ER, PgR, and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005
17. Dowsett M, Allred C: Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 100:S21, 2006 (abstr 48)
18. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005
19. Ma CX, Adjei AA, Salavaggione OE, et al: Human aromatase: Gene resequencing and functional genomics. Cancer Res 65:11071-11082, 2005
20. Moy B, Tu D, Pater JL, et al: Clinical outcomes of ethnic minority women in MA.17: A trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 17:1637-1643, 2006
21. Garber JE, Halabi S, Kaplan E, et al: Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen. J Clin Oncol 23:6S, 2005 (abstr 508)